Ad5.F35-hGCC-PADRE vaccine

A therapeutic cancer vaccine from Scott Waldman's lab at Thomas Jefferson University that teaches the immune system to attack tumors expressing GUCY2C, a receptor normally tucked away inside the gut but exposed on most colorectal, gastric, pancreatic, and small bowel adenocarcinomas. The Phase 2A trial (NCT04111172) finished enrolling 48 patients in the adjuvant (post-surgery, no evidence of disease) setting and is now in safety and immune-response follow-up [1]. This is academic-sponsored work without a public industry partner, so the realistic path to commercial product runs through a licensing deal, not a sponsor-led Phase 3. The target itself is worth taking seriously: druggability is already proven in humans by two approved GUCY2C agonists for GI motility disorders - linaclotide (Linzess, approved for both IBS-C and chronic idiopathic constipation) and plecanatide (Trulance) [5] - and Pfizer's GUCY2C bispecific PF-07062119 plus GUCY2C ADCs at Takeda and others show big pharma is interested in this antigen for GI cancers [6][7]. The vaccine itself is unusual. Most GUCY2C oncology programs are antibodies, bispecifics, or ADCs designed to kill the cancer cell directly. This one trains T cells to do the killing - a different mechanism with different risks. Worth tracking as a target-validation read on GUCY2C in oncology and as a potential priming agent for checkpoint inhibitor combinations in microsatellite-stable colorectal cancer, not a near-term commercial event.

Novel investigational vaccine, never approved anywhere. The Phase 2A study (NCT04111172) at Jefferson is listed as ACTIVE_NOT_RECRUITING with 48 patients enrolled, meaning enrollment is closed and patients are being followed for adverse events and immune responses [1]. No FDA breakthrough, fast track, or orphan designations are on record. A follow-on Phase 1 study (NCT07417488) is recruiting 18 patients with advanced/metastatic colorectal and small bowel adenocarcinoma to test a prime-boost regimen pairing this Ad5.F35 vaccine with a Listeria monocytogenes-based GUCY2C booster (Lm-GUCY2C); the primary endpoint is dose-limiting toxicity to set the recommended Phase 2 boost dose [2]. Listeria-based vaccine platforms use an attenuated (weakened) form of the bacterium that cannot cause disease but preferentially infects antigen-presenting cells, driving strong CD8+ cellular immunity that prolongs and deepens the adenovirus-primed T-cell response - the preclinical basis for this design is published in npj Vaccines 2022 [3]. Both studies are single-arm, academic-sponsored, with Thomas Jefferson University as the only sponsor named publicly. The lab has historically taken several years to translate vaccine readouts into peer-reviewed publication rather than press releases. Timeline for primary completion of the Phase 2A has not been publicly updated and no industry licensing announcements have been disclosed. Expect a journal paper, probably in Clinical Cancer Research or JCI Insight, when the safety and immunogenicity data are mature, with publication realistically targeting mid-2027.

The vaccine teaches T cells to recognize GUCY2C, a receptor stuck on the surface of intestinal lining cells. In healthy gut, GUCY2C does two things: it binds endogenous peptides (guanylin and uroguanylin) that regulate fluid balance, and it serves as the docking site for E. coli's heat-stable enterotoxin, the molecule that causes traveler's diarrhea. The receptor sits only on the luminal (gut-facing) side of intestinal cells, walled off from the immune system by tight junctions. When intestinal cells turn cancerous and metastasize, GUCY2C goes with them and ends up in places the immune system can see, including lymph nodes and liver. That makes it a tumor-associated antigen expressed in roughly 95% of colorectal cancers and the majority of other GI adenocarcinomas, though expression intensity is heterogeneous within and across tumors, and the trial does not pre-select patients by GUCY2C IHC - a biomarker selection question any commercial development plan will need to address. The vaccine uses a chimeric adenovirus (Ad5 capsid with an Ad35 fiber, designed to evade pre-existing immunity to common Ad5) to deliver the GUCY2C gene along with PADRE, a synthetic universal helper-T epitope that recruits CD4 help to amplify the CD8 response [4]. Genetics validate the receptor as biologically real: loss-of-function GUCY2C mutations cause congenital diarrhea, confirming the protein matters in gut physiology. As a tumor antigen, validation comes from Waldman's earlier Phase 1 trial of an Ad5-only version, which showed immune responses against GUCY2C without autoimmune gut toxicity [4]. That is the therapeutic window: hit the tumor, leave the normal gut alone.

NCT04111172 is a single-arm, open-label Phase 2A in patients with GI adenocarcinoma spanning colorectal, gastric, pancreatic, esophageal, and small intestinal histologies [1]. Critically, the enrolled patients are post-resection, curative-intent and no-evidence-of-disease (NED) after completion of standard surgery, chemotherapy, and/or radiation - this is the adjuvant setting, targeting micrometastatic disease after surgery rather than established metastatic tumors. That distinction is commercially load-bearing: adjuvant GI cancer is a large eligible population (over 100,000 colorectal resections annually in the US alone), requires long follow-up for recurrence endpoints, and competes against established adjuvant chemotherapy regimens like FOLFOX and CAPOX rather than late-line salvage therapies. The primary endpoint is incidence of adverse events, so this is fundamentally a safety and immunogenicity study, not a powered efficacy trial. Secondary endpoints include T-cell response measurement and exploratory recurrence assessment. The 48-patient enrollment target has been hit and the trial is now ACTIVE_NOT_RECRUITING. The single-arm AE-focused design tells you the goal: establish safety in a larger patient cohort than the prior Phase 1, document immune response durability, and generate the human pharmacodynamic data needed to design a randomized Phase 2B. The weakness is obvious. No comparator means no clinical benefit claim is possible even if patients do well, and recurrence rates in adjuvant GI cancer vary widely by stage and tumor histology, making any single-arm efficacy signal nearly impossible to interpret. The follow-on Phase 1 prime-boost study (NCT07417488) recruiting 18 patients in advanced/metastatic CRC and small bowel adenocarcinoma adds the Lm-GUCY2C booster to the Ad5.F35 prime, aiming to find a recommended Phase 2 boost dose [2]. The realistic path to a commercial product requires an industry partner to fund a properly powered randomized trial. Jefferson does the immunology well; they are not going to run Phase 3 on their own.

Our model puts this drug's chance of eventual approval at 3%. That figure starts from the historical approval rate for Phase 2 drugs in this area - about 13% - and then adjusts based on ten specific facts about the trial and sponsor. The estimate is pulled down mainly by the sponsor's weak approval record, few secondary endpoints, and limited earlier-phase results; the open-label study design gives it a modest lift. The remaining factors are close to average for this stage and leave the number roughly where it started.

Efficacy is the biggest risk. Therapeutic cancer vaccines have a dismal history in solid tumors outside HPV-positive disease. Sipuleucel-T (Provenge) is the only FDA-approved antigen-specific therapeutic cancer vaccine for a non-viral solid tumor; T-VEC (Imlygic) is separately approved as an oncolytic virus for unresectable melanoma but operates on a different mechanism (direct lytic infection of tumor cells with secondary immune activation) rather than antigen-specific T-cell priming. Both serve as cautionary commercial precedents: Provenge's developer Dendreon went bankrupt and the product was withdrawn from broad US commercial promotion, and T-VEC has remained a niche product despite approval. Even if T-cell responses are induced and measurable, translating those into recurrence-free or overall survival benefit in adjuvant GI cancer is a long bridge. Safety risk is moderate. On-target toxicity could theoretically cause autoimmune enterocolitis if induced T cells reach normal gut epithelium, though the earlier Phase 1 did not show this, likely because GUCY2C sits behind tight junctions on the luminal side [4]. Pre-existing adenovirus immunity is a real concern; the Ad5/Ad35 chimera design addresses Ad5 immunity, but a meaningful fraction of patients carry anti-Ad35 antibodies in some regions, which could blunt vaccine take. Execution risk is high. Academic-sponsored single-arm trials are slow, often delayed, and rarely generate the clean datasets investors and pharma BD teams need for go/no-go decisions. Commercial risk dominates everything else: even with a strongly positive Phase 2A, no company will fund a Phase 3 vaccine trial in adjuvant GI cancer without strong precedent. The realistic path is licensing to a vaccine-focused biotech or an immuno-oncology player that wants a GUCY2C arrow in the quiver, most plausibly Pfizer given their existing GUCY2C bispecific program PF-07062119 [8]. A second, commercially relevant unknown: whether GUCY2C T-cell priming by this vaccine could sensitize microsatellite-stable (MSS) colorectal tumors to checkpoint inhibitors. MSS CRC is the majority of colorectal cancer and does not respond to PD-1/PD-L1 blockade alone - a major unmet need. No vaccine + checkpoint combination data exists for this asset yet, but converting MSS CRC to checkpoint-responsive disease is exactly the value-creation thesis a pharma BD team would explore.

Watch, do not bet. This is credible science from a lab that has owned GUCY2C as a tumor antigen for two decades, but it is an academic-sponsored Phase 2A vaccine in the adjuvant setting with no industry partner and no efficacy comparator. The signal worth watching for: a peer-reviewed publication showing durable T-cell responses against GUCY2C in the Phase 2A cohort, ideally with at least exploratory recurrence data trending the right way. The second signal: an industry licensing announcement, which is the realistic gating event for this program ever reaching a Phase 3 trial. Pfizer is the most logical acquirer given their existing GUCY2C bispecific program PF-07062119, where a vaccine could pair as a priming agent before T-cell engager therapy [8]. The third - and possibly highest-upside - signal: any disclosure of a vaccine + checkpoint inhibitor combination plan, which is the dominant 2026 IO development frame and the most plausible thesis for sensitizing MSS colorectal cancer to PD-1 blockade. Check back in mid-2027 when Phase 2A follow-up should be mature enough for publication and the prime-boost Phase 1 should have dose-finding data [2]. For now, the more commercially relevant GUCY2C nodes to track are the approved GI motility agonists (linaclotide/Linzess co-promoted in the US by AbbVie and Ironwood for both IBS-C and CIC) and the bispecific and ADC programs at Pfizer and Takeda [6][7][8]. This vaccine sits upstream of those programs as a target-validation play, not a near-term commercial story.